UroGen Pharma (URGN) Revenue & Revenue Breakdown
UroGen Pharma Revenue Highlights
Latest Revenue (Y)
$82.71M
Latest Revenue (Q)
$21.85M
Main Segment (Y)
Jelmyto
UroGen Pharma Revenue by Period
UroGen Pharma Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $82.71M | 28.52% |
| 2022-12-31 | $64.36M | 33.96% |
| 2021-12-31 | $48.04M | 307.17% |
| 2020-12-31 | $11.80M | 65450.00% |
| 2019-12-31 | $18.00K | -98.40% |
| 2018-12-31 | $1.13M | -86.17% |
| 2017-12-31 | $8.16M | -53.46% |
| 2016-12-31 | $17.53M | 100.00% |
| 2015-12-31 | - | - |
UroGen Pharma generated $82.71M in revenue during NA 2023, up 28.52% compared to the previous quarter, and up 7332.71% compared to the same period a year ago.
UroGen Pharma Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $21.85M | 16.33% |
| 2024-03-31 | $18.78M | -20.18% |
| 2023-12-31 | $23.53M | 12.84% |
| 2023-09-30 | $20.85M | -1.36% |
| 2023-06-30 | $21.14M | 22.96% |
| 2023-03-31 | $17.19M | -4.97% |
| 2022-12-31 | $18.09M | 12.39% |
| 2022-09-30 | $16.10M | -3.05% |
| 2022-06-30 | $16.60M | 22.41% |
| 2022-03-31 | $13.56M | -16.14% |
| 2021-12-31 | $16.17M | 42.49% |
| 2021-09-30 | $11.35M | -12.90% |
| 2021-06-30 | $13.03M | 74.11% |
| 2021-03-31 | $7.49M | -6.04% |
| 2020-12-31 | $7.97M | 130.16% |
| 2020-09-30 | $3.46M | 830.38% |
| 2020-06-30 | $372.00K | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | -100.00% |
| 2019-06-30 | $18.00K | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | -100.00% |
| 2018-09-30 | $283.00K | -22.25% |
| 2018-06-30 | $364.00K | -24.32% |
| 2018-03-31 | $481.00K | 47.09% |
| 2017-12-31 | $327.00K | -95.81% |
| 2017-09-30 | $7.81M | 100.00% |
| 2017-06-30 | - | -100.00% |
| 2017-03-31 | $19.00K | -99.89% |
| 2016-12-31 | $17.53M | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | - |
UroGen Pharma generated $21.85M in revenue during Q2 2024, up 16.33% compared to the previous quarter, and up 127.08% compared to the same period a year ago.
UroGen Pharma Revenue Breakdown
UroGen Pharma Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 18 |
|---|---|---|---|---|
| Jelmyto | $82.71M | $64.36M | $48.04M | - |
| R T Gel | - | - | - | $1.10M |
UroGen Pharma's latest annual revenue breakdown by segment (product or service), as of Dec 23: Jelmyto (100.00%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Jelmyto | $18.78M | $44.38M | $21.14M | $17.19M | $18.09M | $16.10M | $16.60M | $13.56M | $16.17M | $11.35M |
UroGen Pharma's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Jelmyto (100.00%).
UroGen Pharma Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| OVID | Ovid Therapeutics | $391.69M | $169.00K |
| URGN | UroGen Pharma | $82.71M | $21.85M |
| VACC | Barinthus Biotherapeutics | $44.70M | - |
| IKNA | Ikena Oncology | $9.16M | - |
| KRON | Kronos Bio | $6.29M | $2.69M |
| GBIO | Generation Bio | $5.90M | $4.06M |
| PRTC | PureTech Health | $3.33M | $178.57K |
| INBX | Inhibrx | $1.80M | - |
| CCCC | C4 Therapeutics | - | - |
| TARA | Protara Therapeutics | - | - |
| CNTB | Connect Biopharma | - | - |
| ERAS | Erasca | - | - |
| ELYM | Eliem Therapeutics | - | - |
| CELC | Celcuity | - | - |
| VIGL | Vigil Neuroscience | - | - |
| MACK | Merrimack Pharmaceuticals | - | - |
| ELVN | Enliven Therapeutics | - | - |
| CMPX | Compass Therapeutics | - | - |
| EWTX | Edgewise Therapeutics | - | - |
| SRRK | Scholar Rock | - | - |
| PEPG | PepGen | - | - |
| TYRA | Tyra Biosciences | - | - |
| XLO | Xilio Therapeutics | - | $2.36M |
URGN Revenue FAQ
What is UroGen Pharma’s yearly revenue?
UroGen Pharma's yearly revenue for 2023 was $82.71M, representing an increase of 28.52% compared to 2022. The company's yearly revenue for 2022 was $64.36M, representing an increase of 33.96% compared to 2021. URGN's yearly revenue for 2021 was $48.04M, representing an increase of 307.17% compared to 2020.
What is UroGen Pharma’s quarterly revenue?
UroGen Pharma's quarterly revenue for Q2 2024 was $21.85M, a 16.33% increase from the previous quarter (Q1 2024), and a 3.35% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $18.78M, a -20.18% decrease from the previous quarter (Q4 2023), and a 9.24% increase year-over-year (Q1 2023). URGN's quarterly revenue for Q4 2023 was $23.53M, a 12.84% increase from the previous quarter (Q3 2023), and a 30.06% increase year-over-year (Q4 2022).
What is UroGen Pharma’s revenue growth rate?
UroGen Pharma's revenue growth rate for the last 3 years (2021-2023) was 72.17%, and for the last 5 years (2019-2023) was 459416.67%.
What are UroGen Pharma’s revenue streams?
UroGen Pharma's revenue streams in c 23 are Jelmyto
What is UroGen Pharma’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of UroGen Pharma was Jelmyto. This segment made a revenue of $82.71M, representing 100.00% of the company's total revenue.